Mengesha Abraha Teshome, MD

Instructor in Neurology



  • Medical Degree: Addis Ababa University School of Medicine, Addis Ababa, Ethiopia (1989)
  • Residency in General Surgery: Addis Ababa University School of Medicine, Addis Ababa, Ethiopia (1996)

Research Interests

Dr. Mengesha manages NeuroNEXT clinical trials at Washington University. NeuroNEXT is an acronym for Network for Excellence in NeuroScience Clinical Trials. It is an NIH/NINDS initiative to conduct studies of treatments for neurological diseases within a network of 25 research institutions through partnerships with Academia, private foundations, and industry. The network is designed to expand the National Institute of Neurological Disorders and Stroke’s (NINDS) capability to test promising new therapies, increase the efficiency of clinical trials (including using centralized IRB) before embarking on larger studies, and respond quickly as new opportunities arise to test promising treatments for people with neurological disorders (  Currently our site is participating in all clinical trials that have been supported by the network. Dr. Mengesha’ s primary focus is to facilitate and support the overall research mission of Washington University by introducing and orienting faculty investigators to the NeuroNEXT infrastructure and offer technical support to benefit from this innovative collaborative approach to biomarker-informed clinical research.


  • Clifford DB, Mitike MT, Mekonnen Y, Zhang J, Zenebe G, Melaku Z, Zewde A, Gessesse N, Wolday D, Messele T, Teshome M, Evans S. Neurological evaluation of untreated human immunodeficiency virus infected adults in Ethiopia. J Neurovirol. 2007;13(1):67-72. PubMed PMID: 17454450.
  • Clifford DB, Fagan AM, Holtzman DM, Morris JC, Teshome M, Shah AR, Kauwe JSK. CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology 2009; 73:1982-1987. (PMC2790234)
  • Ances BM, Christensen JJ, Teshome M, Taylor J, Xiong C, Aldea P, Fagan AM, Holtzman DM, Morris JC, Mintun MA, Clifford DB. Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB. A case-control study. Neurology 2010; 75:111-115. (PMC2905926)
  • Ances B, Thomas J, Benzinger T, Christensen J, Teshome M, Aldea P, Fagan A, Holtzman D, Morris J, Clifford D. HIV associated neurocognitive disorder (HAND) is not associated with increased fibrillar amyloid deposits using 11C-PIB in middle-aged HIV+ participants. Ann. Neurol. 2011; 70:S77.

Book Chapters:

  • Voldberding P, Greene W, Lange JMA, Gallant JE. Sande’s HIV/AIDS Medicine: Medical Management of AIDS 2013, 2nd Edition. Philadelphia: Elsevier and Saunders, 2012.